
Default Report

Virtual Primary Care Grand Rounds March 24, 2021 Evaluation- Cerrone Cohen, MD April 5, 2021 8:49 AM EDT


Q1 - To what extent did you find this session useful?



#	Field	Choice	
1	None	0.00%	0
2	Little	0.00%	0
3	A moderate amount	0.00%	0
4	A great deal	13.95%	6
5	Exceptional amount	86.05%	37
			43

Showing rows 1 - 6 of 6

Q2 - What was your overall rating of this session?



#	Field	Choice Count	
1	Poor	0.00%	0
2	Below average	0.00%	0
3	Average	0.00%	0
4	Above Average	2.33%	1
5	Excellent	97.67%	42
			43

Showing rows 1 - 6 of 6

Q3 - What was the most important thing you learned in this session?

What was the most important thing you learned in this session?
Dosing of medications
Adjuncts to poorly controlled depression after SSRI's
Symptoms reduction correlation with response and remission Actions for suboptimal response
considerations for additional medications to augment primary meds
When to change medication and what options do I have
Details regarding prescribing atypical antipsychotics for depression
How to add antipsychotics for pt's with SSRI.
adding 2nd generation antipsychotics to antidepressant
Details on antipsychotic augmentation
Addition of antipsychotics may be helpful if failed SSRIs/SNRIs.
Which meds to augment with ssri's and increasing my comfort level with this
add-on therapy for depression and addressing other non-biological causes of depression
Use of bipolar screening tool. Standardized way to address how to adjust/change/augment SSRI/SNRI treatment
Specific evidence and studies presented and guidance on treatment options
Starting to use mood questionnaire to screen for bipolar
Combination drugs and new approaches
Augmenting strategies for depression
how to manage resistant depression and adding antipsychotics.
Importance of considering bipolar disorder and use of antipsychotics for depression.
Augmentation
how to use 2nd gen antipsychotics to augment
the 50-75% dosing and then to add antipsychotic

What was the most important thing you learned in this session?

Screen for bipolar, how to increase meds, when to add 2nd agent, what are the 2nd agents

screen for bipolar more often using MDQ partial responders to first line med can try augmentation w 2nd gen antipsychotic

practical advice about options for those who achieve only partial response to treatment. and beyond thyroid disorders (which it never is), which medical conditions may truly be complicating the depression picture. and nice reminder to check for bipolar and appreciated validation of the MDQ, which I have used, but wasn't sure that is validated/commonly utilized.

Adding antiphycotics for depression

really helpful to discuss the adding of antipsychotics

practical ways to manage patients with inadequately treated depression

loved all his pearls of wisdom!

How to augment with anti-psycotics

Feel more comfortable that I won't be causing serotonin syndrome by augmenting treatment with additional medications.

maximize dose 50-75% then augment or change

Q4 - What questions do you still have related to the content of this session?

What questions do you still have related to the content of this session?
none
None
Love to hear bipolar disease talk
would like to discuss the differences between the SSRI/SNRIs, and which ones are preferred for which predominant symptom
how can we provide better excess to psychology and psychiatry for patient and providers . Especially in the world of zoom .
Other meds to add besides antipsychotics for depression. Use of thyroid meds in depression Anxiety management including indications for benzos, atarax
None
Any value to do the genetic testing for "med compatibility"?
none
Would love more lectures regarding common mental health topics (bipolar disease for example).
Can we have more sessions like this!?
None
None really
was wondering if you would be able to do a similar talk about management of bipolar disorder in the primary care setting.
None
Nuances on how to use medications
it was great!!
Not much but want to put the things i lesrned into action first
Given that TCAs are a helpful adjunct agent to SSRIs/SNRIs and that they are known to cause serotonin toxicity, what doses are safe to use in combination.
None
any role of checking for the MTFR gene?


What questions do you still have related to the content of this session?

none

Q5 - Do you have recommendations for improving this session?

Do you have recommendations for improving this session?
none
None
MAKE IT LONGER!!!!
None, I wish we had more time with Dr. Cohen!
No! It was excellent!
No - Dr. Cohen has such a pleasing presentation style!!
none- very interactive and easy to follow powerpoint and presentation
No
No it was perfect, hoped it was recorded, it would be great to have these talks/PowerPoints in a library to access in the future.
No
Repeat it in a year
I wish it could have been longer but understand the time constraints. this was very helpful. thanks so much.
None
no
more talks by dr cohen!!
adhd in primary care- do we have to diagnosis with testing? and adding with patients with depression that we just heard.
None. Can Dr. Cohen please do more sessions?
we should have dr cohen more regularly for a mental health series in primary care - he's a wealth of knowledge
No, it was tip-top.
None
no
no - he was great

Q7 - How did you hear about this session?



#	Field	Choice Count
1	Email from colleague/supervisor	37.50% 15
2	Department newsletter/Grand Rounds newsletter	62.50% 25
3	Flier/Poster	0.00% 0
4	Trent Semans digital screen	0.00% 0
5	online calendar	0.00% 0
6	other	0.00% 0

Showing rows 1 - 7 of 7

Q7_6_TEXT - other

other

40

Q9 - If you would like to receive notifications about future Duke Virtual Primary Care

Grand sessions in

If you would like to receive notifications about future Duke Virtual Primar
patrick.gregory@duke.edu
lindsey.goeres@duke.edu
Michael.fedewa@duke.edu
brittney.champagne@duke.edu
morgan.smith@duke.edu
firas.chazli@duke.edu
susan.j.knowles@gmail.com
Christie.ton@duke.edu
ranee.chatterjee@duke.edu
lorraine.anglin@duke.edu
elise.michnowicz@duke.edu

End of Report